Message #32 From:
Stock News Bot Date: November 2, 2006 06:30:00 AM
OXIS News OXIS International CEO Marvin S. Hausman, MD To Present at Rodman & Renshaw's 8th Annual Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--OXIS International, Inc. (OTCBB: OXIS) (Nouveau Marché:
OXIS) (FWB: OXI) today announced that Marvin S. Hausman, MD, the Company’s
Chairman, who was also recently appointed as Chief Executive Officer,
will present at the Rodman
& Renshaw 8th Annual Healthcare Conference in New York on
Wednesday, November 8th , 2006 at 9:30 am U.S. Eastern Time.
OXIS International is a biopharmaceutical company focused on the
research, development and commercialization of diagnostic oxidative
stress biomarkers and nutraceutical and therapeutic products to treat
associated inflammatory disorders.
Rodman & Renshaw will provide a live webcast of the presentation at: http://www.wsw.com/webcast/rrshq10/oxis.ob/
The webcast and the presentation slides will also be archived for 90
days on the Rodman & Renshaw website.
Rodman & Renshaw, LLC is a privately-held, full-service investment bank
focusing on emerging growth companies in the life science and technology
sectors. The firm’s annual healthcare
conference is attended by more than 2,000 delegates and will feature
over 150 emerging growth biotechnology companies in the areas of
oncology, cardiovascular disease, central nervous system disorders,
infectious diseases and medical device technology.
OXIS International, Inc. develops technologies and products to research,
diagnose, treat and prevent diseases of oxidative stress/inflammation
associated with damage from free radical and reactive oxygen species.
The company holds the rights to three therapeutic classes of compounds
in the area of oxidative stress, and has focused commercialization
programs in clinical cardiovascular markers, including MPO
(myeloperoxidase) and GPx (glutathione peroxidase), as well as a highly
potent antioxidant, Ergothioneine, that may be sold over-the-counter
(OTC) as a dietary supplement. OXIS has acquired a 51% interest in and
has the option to purchase the remaining 49% of BioCheck.
BioCheck, Inc. is a leading provider of high quality enzyme immunoassay
research services and products including immunoassay kits for cardiac
and tumor markers, infectious diseases, thyroid function, steroids, and
fertility hormones. The company operates a 15,000 square-foot, U.S. Food
and Drug Administration (FDA) certified cGMP, and ISO
device-manufacturing facility in Foster City, California. BioCheck has
advanced developmental programs on two promising cancer biomarkers,
related to the Id-gene, and the HMGA2 gene. Id proteins play a
significant role in the process of tumor related angiogenesis and other
functions related to blood vessel formation. The HMGA2 gene has been
implicated in aggressive forms of breast cancer.
